What does Passage Bio, Inc. do?
Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; PBGM01, a functional GLB1 gene encoding ß-galactosidase for…
What is Passage Bio, Inc.'s P/E and P/B ratio?
Passage Bio, Inc. has a P/E ratio of -0.3 and a P/B ratio of 2.53.
What is Passage Bio, Inc.'s debt-to-equity ratio?
Passage Bio, Inc. has a debt-to-equity ratio of 1.28.
How much does Passage Bio, Inc. owe compared with what it owns?
Passage Bio, Inc. owes $0.82 for every $1 it owns (balance sheet Jun 2026), which is high.
What is Passage Bio, Inc.'s Positivity rank?
Passage Bio, Inc. is ranked #3,080 of 6,774 companies globally and #1,198 of 4,000 in United States on PositoAI, with a Positivity Score of 20,883.
Does Passage Bio, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for Passage Bio, Inc..
Where can I read the latest news about Passage Bio, Inc.?
Recent headlines about Passage Bio, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does Passage Bio, Inc. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of Passage Bio, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.